---
title: "Onco-Innovations starts polymer process development, characterization program for ONC010 nanoparticle PNKP inhibitor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291338981.md"
description: "Onco-Innovations has initiated polymer process development and analytical characterization for ONC010, its lead nanoparticle-formulated PNKP inhibitor. Nanosoft Polymers is optimizing polymer synthesis and establishing core analytical methods to ensure reproducible manufacturing and future scale-up. This program aims to create a scalable polymer platform to support formulation development, technology transfer, GMP readiness, regulatory filings, and clinical progression."
datetime: "2026-06-30T22:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291338981.md)
  - [en](https://longbridge.com/en/news/291338981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291338981.md)
generator: "portal-rs"
---

# Onco-Innovations starts polymer process development, characterization program for ONC010 nanoparticle PNKP inhibitor

-   Onco-Innovations launched polymer process development and analytical characterization work for ONC010, its lead nanoparticle-formulated PNKP inhibitor. \* Nanosoft Polymers is optimizing polymer synthesis and building core analytical methods to support reproducible manufacturing and future scale-up. \* The program targets a scalable polymer platform to underpin formulation development, technology transfer, GMP readiness, regulatory filings, and clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606301800ACCESSWRNAPR\_\_\_\_\_1184800) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md)

## Related News & Research

- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program](https://longbridge.com/en/news/296513179.md)
- [Onco-Innovations identifies non-tin catalyst to advance ONC010 polymer development](https://longbridge.com/en/news/295714977.md)
- [PharmAla Biotech says USPTO grants US patent for enantioselective MDMA, MBDB processes](https://longbridge.com/en/news/296608164.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [Bioextrax patent application enters regulatory review for new molasses-based PHA process](https://longbridge.com/en/news/296315743.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**